Market Overview

UPDATE: Wedbush Lowers PT to $9 on Idenix Pharmaceuticals; IDX184 on Clinical Hold

Share:
Related IDIX
What Investors Are Watching For In Regulus Therapeutics' Next Data Release
Wall Street's Hall Of Fame (And Hall Of Shame): The Best And Worst Analyst Recommendations Of 2014

Wedbush reiterated its Outperform rating on Idenix Pharmaceuticals (NASDAQ: IDIX) but lowered its price target from $14 to $9.

Wedbush commented, "We are adjusting our model to reflect several recent events for Idenix: (1) Novartis agreement restructuring; (2) $150MM financing; (3) Bristol-Myers' nuc (BMS-094) setback and (4) subsequent clinical hold on IDX184. The net result is our new fair value of $9. We maintain our OUTPERFORM rating due to the favorable risk/reward profile with shares now trading below $6. Moreover, we still see significant upside upon positive Phase II combination data and believe the added risks are already reflected in the current share price."

Idenix Pharmaceuticals closed at $5.90 on Friday.

Latest Ratings for IDIX

DateFirmActionFromTo
Jun 2014UBSDowngradesBuyNeutral
Jun 2014BairdUpgradesUnderperformNeutral
Jan 2014JMP SecuritiesDowngradesMarket PerformMarket Underperform

View More Analyst Ratings for IDIX
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings

 

Related Articles (IDIX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional